专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20170248595A1 KIT AND METHOD 审中-公开
公开(公告)号：US20170248595A1
公开(公告)日：2017-08-31
申请号：US15503627
申请日：2015-08-13
申请人： Diagnostig LTD
发明人： Mark Stephen Baird , Christopher David Gwenin , Vanessa Valerie Gwenin , Joanne Louise Hacking , Mark Pitts
IPC分类号： G01N33/569 , G01N33/543 , G01N33/553
CPC分类号： G01N33/5695 , G01N33/543 , G01N33/54366 , G01N33/553 , G01N33/558 , G01N33/92 , G01N2333/35 , G01N2405/00 , G01N2800/50
摘要： A method of determining the presence or absence in a sample of a biomarker, the method comprising the steps of (a) providing a porous substrate which carries an antigen; (b) contacting the substrate with the sample; (c) contacting the substrate with a composition comprising a secondary antibody; and (d) observing the substrate. The method may enable a very quick, simple test to be carried out to determine whether or not a particular sample contains a biomarker, for example an antibody indicative of infection with a mycobacterial disease. A kit and a device for determining the presence or absence in a sample of a biomarker are also described.

72. 发明授权

US09726683B2 Methods for predicting risk of coronary stenosis 有权
公开(公告)号：US09726683B2
公开(公告)日：2017-08-08
申请号：US14948938
申请日：2015-11-23
申请人： Wake Forest University Health Sciences
发明人： Lawrence L. Rudel , Chadwick D. Miller , Michael J. Thomas
IPC分类号： G01N33/92 , G06F19/00
CPC分类号： G01N33/92 , G01N2405/00 , G01N2560/00 , G01N2800/323 , G01N2800/50 , G01N2800/56 , G06F19/00 , G16H50/30
摘要： A computer-based method for determining a prediction of risk and/or an indication of extent of coronary stenosis in a human subject, comprises the steps of: (a) inputting the level of at least one cholesteryl ester measured in a blood sample collected from said subject; and then (b) inputting the age and gender of said subject; and then (c) generating in said computer from said cholesteryl ester level input, said age input and said gender input a prediction of risk and/or an indication of extent of coronary stenosis in said subject. Systems and methods are also described.

73. 发明申请

US20170204415A1 Compositions of Matter that Reduce Pain, Shock, and Inflammation by Blocking Linoleic Acid Metabolites and Uses Thereof 审中-公开
公开(公告)号：US20170204415A1
公开(公告)日：2017-07-20
申请号：US15444706
申请日：2017-02-28
申请人： Board of Regents of the University of Texas System
发明人： Kenneth Michael Hargreaves , John Gordon Bruno
IPC分类号： C12N15/115 , A61K31/192 , G01N33/53 , A61K31/56 , G01N33/92 , A61K45/06 , A61K31/7088
CPC分类号： C12N15/115 , A61K31/192 , A61K31/56 , A61K31/7088 , A61K45/06 , A61K47/549 , A61K47/55 , A61K47/60 , C12N2310/16 , C12N2310/351 , C12N2310/3515 , C12N2310/3519 , C12N2320/30 , C12N2320/32 , G01N33/5308 , G01N33/92 , G01N2405/00 , G01N2800/2842
摘要： A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs.

74. 发明授权

US09687461B2 Method for detecting risk factor for metabolic syndrome or hyperferritinemia 有权
公开(公告)号：US09687461B2
公开(公告)日：2017-06-27
申请号：US14980695
申请日：2015-12-28
申请人： Stephanie Venn-Watson
发明人： Stephanie Venn-Watson
IPC分类号： A61K31/20 , A61K31/202 , A61K31/201 , G01N33/92
CPC分类号： A61K31/20 , A61K31/201 , A61K31/202 , G01N33/92 , G01N2405/00 , G01N2800/04 , G01N2800/042 , G01N2800/22 , G01N2800/50
摘要： Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.

75. 发明申请

US20160363602A1 LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS UNDERGOING STATIN TREATMENT 审中-公开
公开(公告)号：US20160363602A1
公开(公告)日：2016-12-15
申请号：US15249935
申请日：2016-08-29
申请人： Zora Biosciences OY
发明人： Reijo Laaksonen , Kim Ekroos , Reini Hurme , Riikka Katainen
IPC分类号： G01N33/92
CPC分类号： G01N33/92 , G01N2405/00 , G01N2560/00 , G01N2570/00 , G01N2800/32 , G01N2800/324 , G01N2800/325 , G01N2800/50 , G01N2800/70 , H01J49/0027
摘要： The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

76. 发明申请

US20160327578A1 CHOLESTEROL EFFLUX CAPACITY ASSESSMENT 审中-公开
标题翻译：胆固醇消耗能力评估
公开(公告)号：US20160327578A1
公开(公告)日：2016-11-10
申请号：US14706834
申请日：2015-05-07
申请人： Boston Heart Diagnostics Corporation
发明人： Bela F. Asztalos , Michael Riel-Mehan , Ernst J. Schaefer
IPC分类号： G01N33/92
CPC分类号： G01N33/92 , G01N2405/00 , G01N2500/04 , G01N2800/32 , G01N2800/50 , G01N2800/52 , G16B20/00 , G16H50/20 , G16H50/30
摘要： A method is provided for transforming one or more biomarkers into a cholesterol efflux capacity (CEC) level. Methods relate to determining SR-BI-mediated and ABCA1-mediated CEC. CEC may be used for compound screening and to determine risk of cardiovascular disease and to recommend or administer treatment regimens.
摘要翻译：提供了将一种或多种生物标志物转化为胆固醇流出能力（CEC）水平的方法。方法涉及确定SR-BI介导的和ABCA1介导的CEC。 CEC可用于化合物筛选和确定心血管疾病的风险，并推荐或施用治疗方案。

77. 发明申请

US20160245786A1 LIPID BIOMARKERS OF HEALTHY AGEING 审中-公开
标题翻译：健康老化的脂肪生物标志物
公开(公告)号：US20160245786A1
公开(公告)日：2016-08-25
申请号：US15028244
申请日：2014-11-05
申请人： NESTEC S.A.
发明人： Sebastiano Collino , Ivan Montoliu Roura , Françios-Pierre Martin , Fiona Camille Beguelin , Serge André Dominique Rezzi
IPC分类号： G01N33/487
CPC分类号： G01N33/487 , G01N33/6893 , G01N33/92 , G01N2405/00 , G01N2405/02 , G01N2405/04 , G01N2405/08 , G01N2560/00 , G01N2570/00 , G01N2800/50 , G01N2800/52
摘要： In one aspect there is provided a method for predicting a risk of unhealthy ageing in a subject, comprising: (a) determining a level of two or more lipid biomarkers in a sample from the subject, wherein the biomarkers are selected from two or more of the following groups: (i) a triacylglycerol (TAG) from TAG (46:5) to TAG (54:3); (ii) an ether phosphatidylcholine (PC-O) from PC-O(28:0) to PC-O(38:6); (iii) a sphingomyelin (SM) from SM (33:1) to SM(50:1); (iv) a phosphatidylcholine (PC) from PC (32:1) to PC (40:5); (v) a phosphatidylinositol (PI) from PI (36:1) to PI (38:3); (vi) a phosphatidylethanolamine (PE) from PE (36:2) to PE (38:4); and (b) comparing the levels of the biomarkers in the sample to reference values; wherein the levels of the biomarkers in the sample compared to the reference values are indicative of the risk of unhealthy ageing in the subject.
摘要翻译：一方面，提供了一种用于预测受试者中不健康衰老风险的方法，其包括：（a）测定来自所述受试者的样品中两种或更多种脂质生物标志物的水平，其中所述生物标志物选自以下组：（i）TAG（46:5）至TAG（54:3）的三酰基甘油（TAG）; （ii）从PC-O（28:0）到PC-O（38:6）的醚磷脂酰胆碱（PC-O）; （iii）SM（33：1）至SM（50：1）的鞘磷脂（SM）; （iv）从PC（32:1）到PC（40:5）的磷脂酰胆碱（PC）; （v）PI（36：1）至PI（38：3）的磷脂酰肌醇（PI）; （vi）从PE（36:2）到PE（38:4）的磷脂酰乙醇胺（PE）; 和（b）将样品中生物标志物的水平与参考值进行比较; 其中与参考值相比，样品中的生物标志物的水平表明受试者中不健康老化的风险。

78. 发明申请

US20160195559A1 Method For Detecting Risk Factor For Metabolic Syndrome or Hyperferritinemia 有权
标题翻译：检测代谢综合征或高铁蛋白血症危险因素的方法
公开(公告)号：US20160195559A1
公开(公告)日：2016-07-07
申请号：US14980695
申请日：2015-12-28
申请人： Stephanie Venn-Watson
发明人： Stephanie Venn-Watson
IPC分类号： G01N33/92
CPC分类号： A61K31/20 , A61K31/201 , A61K31/202 , G01N33/92 , G01N2405/00 , G01N2800/04 , G01N2800/042 , G01N2800/22 , G01N2800/50
摘要： Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.
摘要翻译：用于检测根据若干实施方案的代谢综合征或高铁蛋白血症的风险和/或原因的方法可以包括测量受试者血液样品中十七烷酸水平的步骤。如果十七烷酸的量低于血清或血浆中所有脂肪酸的0.4％，则几个实施方案的方法还可包括将受试者认为具有或处于代谢综合征风险的步骤。根据若干实施方案的治疗代谢综合征或高铁蛋白血症的方法还可以包括向患有代谢综合征或高铁蛋白血症的受试者施用日剂量的十七烷酸一段时间从三周到二十四周的步骤，其中最小日剂量包含约3mg / lb（或6mg / kg）体重。

79. 发明申请

US20160103144A1 BLOOD BASED METHODS OF ASSESSING ADOLESCENT DEPRESSION IN A SUBJECT 审中-公开
标题翻译：基于血液的方法评估受试者的ADOLESCENT DEPRESSION
公开(公告)号：US20160103144A1
公开(公告)日：2016-04-14
申请号：US14974239
申请日：2015-12-18
申请人： True Health Diagnostics, LLC
发明人： William S. Harris , James V. Pottala , Andrew B. Christianson
IPC分类号： G01N33/92 , G06F19/00
CPC分类号： G01N33/92 , G01N2405/00 , G01N2570/00 , G01N2800/304 , G01N2800/38 , G16H50/30
摘要： The present invention provides blood based methods for assessing adolescent depression in a subject.
摘要翻译：本发明提供用于评估受试者中青少年抑郁症的基于血液的方法。

80. 发明申请

US20160052982A1 METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS 审中-公开
标题翻译：用于设计和/或表征可溶性脂肪配体剂的方法和系统
公开(公告)号：US20160052982A1
公开(公告)日：2016-02-25
申请号：US14783489
申请日：2014-03-13
申请人： TUFTS MEDICAL CENTER , TRUSTEES OF TUFTS COLLEGE
发明人： Charles Cohen , Krishna Kumar , Jamie Raudensky Doyle , Alan S. Kopin
IPC分类号： C07K14/47 , C07K7/06 , C07K7/08 , G01N33/50
CPC分类号： C07K14/4703 , A61K38/00 , A61K47/543 , C07K7/06 , C07K7/08 , G01N33/5023 , G01N33/92 , G01N2405/00 , G01N2440/10
摘要： The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.
摘要翻译：本申请提供了制备包含配体实体和脂质实体的可溶性脂质化配体试剂的方法，并且在一些实施方案中提供了这些组分中的每一个的相关参数，从而使得能够适当选择组分以组合任何给定目标靶标的活性剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式